Editas Medicine (EDIT)

Jan 17, 2025, 12:20 PM EST - 14 hours ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 2 days ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 4 days ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 11 days ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 5 weeks ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 5 weeks ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 5 weeks ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 5 weeks ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 6 weeks ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 7 weeks ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 2 months ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 6, 2024, 9:00 AM EST - 2 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Nov 4, 2024, 7:30 AM EST - 2 months ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 3 months ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 3 months ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 3 months ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 3 months ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 3 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 3 months ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 3 months ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 4 months ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 4 months ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 4 months ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 4 months ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Aug 7, 2024, 12:03 PM EDT - 5 months ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 5 months ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Jul 31, 2024, 7:00 AM EDT - 6 months ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jun 14, 2024, 3:01 AM EDT - 7 months ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 7 months ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

May 15, 2024, 8:25 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)

May 14, 2024, 10:00 AM EDT - 8 months ago

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 10, 2024, 6:00 AM EDT - 9 months ago

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 8, 2024, 10:57 AM EDT - 9 months ago

Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 9 months ago

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 2, 2024, 7:00 AM EDT - 9 months ago

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 1, 2024, 8:00 AM EDT - 9 months ago

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Apr 22, 2024, 4:31 PM EDT - 9 months ago

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 13, 2024, 7:58 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Mar 12, 2024, 3:56 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)

Mar 6, 2024, 5:05 PM EST - 11 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)

Feb 28, 2024, 4:52 PM EST - 11 months ago

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28, 2024, 11:11 AM EST - 11 months ago

Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:00 AM EST - 11 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb 21, 2024, 7:00 AM EST - 11 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Feb 13, 2024, 1:14 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

Feb 7, 2024, 2:00 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)

Jan 10, 2024, 12:43 AM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Jan 8, 2024, 8:15 AM EST - 1 year ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 9:00 AM EST - 1 year ago

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9